January 16, 2017 7:00 AM ET


Company Overview of Teva Pharmaceuticals USA, Inc.

Company Overview

Teva Pharmaceuticals USA, Inc. manufactures and markets generic drugs in the United States. It offers generic products for various therapeutic options, such as cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatologic, respiratory, and women’s health. The company offers its products in various dosage forms, such as tablets, capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. It serves patients through distributors. Teva Pharmaceuticals USA, Inc. was formerly known as Lemmon Pharmacal Company and changed its name to Teva Pharmaceuticals USA, Inc. in 1996. The company was founded in 1945 and is base...

1090 Horsham Road

North Wales, PA 19454

United States

Founded in 1945





Key Executives for Teva Pharmaceuticals USA, Inc.

Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Compensation as of Fiscal Year 2016.

Teva Pharmaceuticals USA, Inc. Key Developments

Mayne Pharma Group Limited, Mylan, Teva Pharmaceuticals, Hewritage Pharmaceuticals, Aurobindo Pharma and Citron Pharma Face Lawsuit

Mayne Pharma disclosed that it been issued a subpeona by the anti trust division of the US Department of Justice in relation to marketing, pricing and sales of doxycycline hyciate delayed release antibiotic tablets and potassiumhloride powders. 20 US states had begun legal proceedings in the US District Court of Connecticut against several generic companies, alleging that senior executives had fixed prices for antiobiotics and oral diabetes medication. The suit was filed against Mayne Pharma as well as Mylan, Teva Pharmaceuticals, Hewritage Pharmaceuticals, Aurobindo Pharma and Citron Pharma, with the states alleging company executives propped up the prices of the two drugs.

Cephalon, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., and Barr Pharmaceuticals, Inc. Announce Settlement for Purchasers of Provigil® or Generic Versions of Provigil® (Modafinil)

A proposed settlement has been reached in a lawsuit regarding the price that individuals in 48 states and the District of Columbia paid for Provigil® and generic versions of Provigil®.  The lawsuit asserts that defendants Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., and Barr Pharmaceuticals, Inc., (all collectively, "defendants") violated antitrust laws relating to the sale of the prescription pharmaceutical Provigil®. All defendants have denied any wrongdoing. Provigil (modafinil) is used to treat excessive sleepiness caused by sleep apnea, narcolepsy, or shift work sleep disorder. If customers have purchased Provigil® and/or modafinil between June 24, 2006 and March 31, 2012, may be entitled to a payment from the settlement fund. The defendants will pay a total of $35 million into a settlement fund to settle all claims in the lawsuit brought on behalf of consumers. The Settlement Fund will be distributed pro rata to consumers who file a valid Claim Form.

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Enters into an Agreement with Teva Pharmaceuticals USA, Inc

The board of directors of CSPC Pharmaceutical Group Limited announced that on 9 December 2016, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. entered into an agreement with Teva Pharmaceuticals USA, Inc. in relation to the product licensing and commercialization of a complex antibiotic injectable generic drug (the "Product") in the United States of America and countries in the European Union. The Product is under development by CSPC Zhongqi utilizing its proprietary technology. Pursuant to the Agreement, CSPC Zhongqi is responsible for the pre-clinical development of the Product and know-how in relation to the manufacturing of the Product and preparation of documentation according to both US and EU requirements for drug application. CSPC Zhongqi agrees to grant an exclusive right to Teva to perform the necessary non-clinical and clinical studies and apply for the relevant approvals required for the distribution and sale of the Product in the Territory and to exclusively distribute and sell the Product in the Territory. Teva will make milestone payments to CSPC Zhongqi of up to an aggregate amount of $100,000,000 subject to the Product's application progress and amount of future sales in the Territory. Upon successful launch of the Product in the Territory, CSPC Zhongqi shall supply the Product exclusively to Teva, and Teva shall purchase exclusively from CSPC Zhongqi such quantities of the Product that Teva requires for distribution and sale in the Territory. CSPC Zhongqi will also be entitled to receive a prescribed percentage of the net profits with respect to the sale of the Product in the Territory from Teva.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

August 23, 2016
Frank W. Kerr Inc.
June 21, 2016
Portfolio of Generic Products

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Teva Pharmaceuticals USA, Inc., please visit www.tevausa.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.